{"ticker":"RVMD","companyName":"Revolution Medicines, Inc.","fiscalYear":2025,"executiveName":"Mark A. Goldsmith","executiveTitle":"M.D., Ph.D.","totalComp":14672390,"salary":812500,"stockAwards":3968076,"optionAwards":8995114,"nonEquityIncentive":889700,"otherComp":7000,"yoyChangePct":45.566775147673624,"source":{"filingType":"DEF 14A","accession":"0001193125-26-182453","filingDate":"2026-04-27","filingUrl":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526182453/d111313ddef14a.htm"},"lastUpdated":"2026-07-03T09:25:43.548Z","yoy_total_comp_pct":45.566775147673624}